LUCENTIS Rx

Select the drug indication to add to your list

LUCENTIS

Miscellaneous ocular agents
Only 4 drugs may be compared at once

Generic Name and Formulations:

Ranibizumab 6mg/mL, 10mg/mL; soln for oph intravitreal inj; preservative-free.

Company:

Genentech, Inc.

Select therapeutic use:

Indications for LUCENTIS:

Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).

Adult:

Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.

Children:

Not established.

Contraindications:

Ocular or periocular infections.

Warnings/Precautions:

Monitor intraocular pressure prior to and 30 mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Risk of embryo-fetal toxicity. Pregnancy. Nursing mothers.

Pharmacological Class:

Vascular endothelial growth factor (VEGF) inhibitor.

Adverse Reactions:

Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events.

Generic Availability:

NO

How Supplied:

Single-use prefilled syringe (10mg/mL)—1; Single-use vial (6mg/mL, 10mg/mL)—1

LUCENTIS 0.05ml of 0.5mg vials (Qty:1)

appx. price $2106.00